UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Blood, 2017-11, Vol.130 (19), p.2055-2063

2017

Volltextzugriff (PDF)

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Blood, 2015-08, Vol.126 (9), p.1078-1085

2015

Volltextzugriff (PDF)

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

Blood, 2012-01, Vol.119 (2), p.612-618

2012

Volltextzugriff (PDF)

Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina

Circulation research, 2011-08, Vol.109 (4), p.428-436

2011

Volltextzugriff (PDF)

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Blood, 2021-02, Vol.137 (6), p.763-774

2021

Volltextzugriff (PDF)

Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19

Thrombosis research, 2021-05, Vol.201, p.100-112

2021

Volltextzugriff (PDF)

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

Blood, 2013-08, Vol.122 (5), p.648-657

2013

Volltextzugriff (PDF)

Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors

Thrombosis and haemostasis, 2017-12, Vol.117 (12), p.2267-2273

2017

Volltextzugriff (PDF)

Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature

American journal of hematology, 2008-02, Vol.83 (2), p.137-143

2008

Volltextzugriff (PDF)

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

The New England journal of medicine, 2017-11, Vol.377 (22), p.2193-2195

2017

Volltextzugriff (PDF)

Advancing personalized care in hemophilia A : ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Biologics, 2014-01, Vol.8 (Apr 5), p.115-127

Berntorp, Erik

2014

Volltextzugriff (PDF)

Patient Experience with Congenital (Hereditary) Thrombotic Thrombocytopenic Purpura: A Conceptual Framework of Symptoms and Impacts

The patient : patient-centered outcomes research, 2019-10, Vol.12 (5), p.503-512

2019

Volltextzugriff (PDF)

Psychometric evaluation of a patient-reported outcomes instrument for congenital thrombotic thrombocytopenic purpura

Journal of patient-reported outcomes, 2023-07, Vol.7 (1), p.68-68, Article 68

2023

Volltextzugriff (PDF)

The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease

Hamostaseologie, 2017, Vol.37 (S 01), p.S15-S25

2017

Volltextzugriff (PDF)

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Thrombosis and haemostasis, 1998-12, Vol.80 (6), p.912-918

1998

Volltextzugriff (PDF)

Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients

Thrombosis and haemostasis, 2008-08, Vol.100 (2), p.217-223

2008

Volltextzugriff (PDF)

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study

Blood, 2002-01, Vol.99 (2), p.450-456

2002

Volltextzugriff (PDF)

Regulated secretion in endothelial cells: biology and clinical implications

Thrombosis and haemostasis, 2001-11, Vol.86 (5), p.1148-1155

2001

Volltextzugriff (PDF)

Bleeding reduction during secondary prophylaxis with bypassing agents in inhibitor patients

Thrombosis research, 2011-02, Vol.127 (2), p.174-175

2011

Volltextzugriff (PDF)

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B

Transfusion (Philadelphia, Pa.), 2002-02, Vol.42 (2), p.190-197

2002

Volltextzugriff (PDF)

Estimation of the Economic Burden Associated with Major Surgery Due to Von Willebrand Disease Based on Claims Data from the USA

Blood, 2019-11, Vol.134 (Supplement_1), p.4692-4692

2019

Volltextzugriff (PDF)

Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States

Journal of managed care & specialty pharmacy, 2021-02, Vol.27 (2), p.175-185

2021

Volltextzugriff (PDF)

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Blood, 2021-04, Vol.137 (13), p.1818-1827

2021

Volltextzugriff (PDF)

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

Expert opinion on biological therapy, 2009-03, Vol.9 (3), p.273-283

2009

Volltextzugriff (PDF)

Continuous infusion of recombinant factor VIIa: continue or not?

Thrombosis and haemostasis, 2001-10, Vol.86 (4), p.942-944

Ewenstein, B M

2001

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(123)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Life Sciences & Biomedicine
(67)
Humans
(60)
Hematology
(41)
Biological And Medical Sciences
(34)
Medical Sciences
(28)
Male
(24)
Adult
(22)
Adolescent
(19)
Female
(18)
Middle Aged
(18)
Child
(15)
Cardiovascular System & Cardiology
(14)
Hematologic And Hematopoietic Diseases
(14)
Hemophilia A - Drug Therapy
(14)
Child, Preschool
(13)
Infant
(13)
Factor Viii
(11)
Peripheral Vascular Disease
(11)
Platelet Diseases And Coagulopathies
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors

Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Advancing personalized care in hemophilia A : ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Patient Experience with Congenital (Hereditary) Thrombotic Thrombocytopenic Purpura: A Conceptual Framework of Symptoms and Impacts

Psychometric evaluation of a patient-reported outcomes instrument for congenital thrombotic thrombocytopenic purpura

The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study

Regulated secretion in endothelial cells: biology and clinical implications

Bleeding reduction during secondary prophylaxis with bypassing agents in inhibitor patients

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B

Estimation of the Economic Burden Associated with Major Surgery Due to Von Willebrand Disease Based on Claims Data from the USA

Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

Continuous infusion of recombinant factor VIIa: continue or not?

Suchergebnisse filtern